RaQualia Pharma Inc.
4579.T · JPX
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | ¥8,312 | ¥14,865 | ¥25,834 | ¥24,599 |
| - Cash | ¥3,142 | ¥3,715 | ¥3,675 | ¥2,345 |
| + Debt | ¥3,452 | ¥368 | ¥222 | ¥39 |
| Enterprise Value | ¥8,622 | ¥11,518 | ¥22,381 | ¥22,293 |
| Revenue | ¥3,108 | ¥1,901 | ¥2,918 | ¥2,776 |
| % Growth | 63.5% | -34.8% | 5.1% | – |
| Gross Profit | ¥2,482 | ¥1,656 | ¥2,686 | ¥2,456 |
| % Margin | 79.9% | 87.1% | 92.1% | 88.4% |
| EBITDA | ¥188 | -¥112 | ¥1,005 | ¥1,024 |
| % Margin | 6.1% | -5.9% | 34.4% | 36.9% |
| Net Income | -¥495 | -¥324 | ¥723 | ¥756 |
| % Margin | -15.9% | -17% | 24.8% | 27.2% |
| EPS Diluted | -22.87 | -14.98 | 34.47 | 36.04 |
| % Growth | -52.7% | -143.5% | -4.4% | – |
| Operating Cash Flow | ¥181 | -¥719 | ¥1,480 | ¥366 |
| Capital Expenditures | -¥97 | -¥222 | -¥32 | -¥105 |
| Free Cash Flow | ¥84 | -¥941 | ¥1,448 | ¥261 |